Day Two

• Identify the limitations of standard-ofcare AML MRD assays: Understand how bulk NGS and multiparameter flow cytometry (MFC) can yield false negatives and false positives due to complex clonal evolution, phenotypic shifts, and overlapping immunophenotypes
• Evaluate comparative clinical data: Single-cell AML MRD clinical study data demonstrates how single-cell multiomics achieves superior sensitivity (93%) compared to traditional flow cytometry (43%) and molecular methods (71%), offering a more accurate stratification of relapse-free survival
• Redefining the future of AML MRD clinical evaluation: Single-cell multi-omics in AML MRD analysis provides the clinical evidence required to anticipate relapse better, establish deciding factors for interventions like treatment consolidation, targeted therapeutic pivoting, and clinical trial stratification

• Outlining a strategy for integrating diverse data streams, from molecular biomarkers to advanced imaging, to create a unified view of patient response
• Discussing how real-time insights from biomarkers and imaging can inform dynamic adjustments to drug dosage and treatment schedules, moving beyond traditional safety metrics
• Exploring how this integrated approach can provide a more robust and evidence based foundation for making critical decisions about advancing the drug to a larger trial

Presentation Details to be Announced 

• When should biomarker evidence trigger CDx development, and how can strategies align with therapeutic goals, clinical endpoints, and regulatory requirements?
• How can organizations build adaptable CDx strategies that support clinical development while addressing regional differences in regulation, testing infrastructure, and clinical practice?
• What is the impact of regulations, and added considerations for executing this strategy, partnerships and co-development?

• Essential attributes of a high‑performing CDx
• Executing complex, multi‑stakeholder CDx programs
• How CDx experience accelerates market, regulatory, and clinical success

• Reviewing critical decision points to ensure Rx-Dx success
• The path to clinical adoption for novel tests
• Role of stakeholders across the ecosystem, including genetic counselors

Inquire about remaining partnership opportunities at sponsor@hansonwade.com

• How can biopharma and diagnostics partners truly synchronize drug-CDx launches to avoid misalignment in assay availability, regulatory timing, and clinical adoption across markets?
• What are the biggest barriers to global drug-CDx adoption at launch, and how can they be proactively addressed within commercialization strategies?
• In an increasingly complex global landscape, how can organizations balance the need for standardized CDx strategies with local market realities to achieve equitable patient access?

• Tumor heterogeneity determines treatment response and resistance, and AI-powered computational pathology makes heterogeneity tractable for drug development
• Tissue analysis succeeds in drug development when scientific, computational, and delivery expertise are integrated from the start, not assembled project by project
• Connecting imaging features to outcomes to generate predictive biomarkers, and translation into cross-cohort and cross-platform validation and deployment
• Infrastructure and global access shape which biomarkers can actually reach patients. H&E-based approaches can have an important role in ensuring equitable, global CDx access

• Target expression in indication selection and as potential predictive biomarkers
• Digital pathology approaches and technical challenges
• Optimizing program investment and deciding what data will be enough

• Discover how Deciphex combines expert pathology insight with its proprietary AI engine, CipherX, to support companion diagnostic (CDx) and biomarker trials
• Explore how intelligent analysis of pathology images can help research teams find meaningful patterns in tissue data and inform trial decisions

Presentation Details to be Announced

• Bioptimus has created M-Optimus, the first World Model of Biology, underpinned with the Spatial Tissue Embedding Learning Atlas (STELA)
• By leveraging a massive multimodal repository of patient data, M-Optimus enables mapping of cellular interactions across oncology and immunology at an unprecedented scale
• We will present the latest data demonstrating how this global infrastructure enables researchers to predict high-resolution spatial mapping from standard H&E stained slides, allowing new predictive insights for therapeutic response
• Find out how these multimodal signatures can redefine CDx and de-risk the drug development pipeline

• Discussing efforts to integrate proteomics, metabolomics, lipidomics, imaging, digital phenotyping, longitudinal natural history study data, and patient-reported outcomes into comprehensive biosignatures that provide a multidimensional view of disease progression in rare neurodegenerative disorders
• Exploring how ML approaches enable identification of biologically meaningful biomarker combinations that more sensitively capture disease progression and therapeutic response than traditional single-analyte biomarkers
• Showing future applications ranging from clinical trial readiness and surrogate endpoint development to newborn screening and earlier disease detection in genetically defined disorders

Inquire about remaining partnership opportunities at sponsor@hansonwade.com

• Where do leading technology companies see the greatest unrealized promise and unmet need in precision medicine today, and which technology innovations are required to unlock meaningful clinical and commercial impact?
• How can AI-driven biomarker discovery, precision stratification, and patient- or population-level digital twins be operationalized at scale, and what infrastructure, data strategies, and partnerships are required to make this a clinical reality?